BWX Technologies Submits Drug Master File To US Food And Drug Administration For No Carrier Added Actinium-225 Active Pharmaceutical Ingredient
Portfolio Pulse from Benzinga Newsdesk
BWX Technologies' medical subsidiary, BWXT Medical Ltd., has submitted a Drug Master File to the FDA for No Carrier Added Actinium-225, an isotope used in targeted alpha therapies for cancer treatment.
June 07, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BWX Technologies' medical subsidiary has submitted a Drug Master File to the FDA for No Carrier Added Actinium-225, an isotope used in targeted alpha therapies for cancer treatment. This regulatory step could potentially open new revenue streams for BWXT in the medical field.
The submission of a Drug Master File to the FDA is a significant regulatory step that could lead to the approval and commercialization of No Carrier Added Actinium-225. This could open new revenue streams for BWXT in the medical field, particularly in cancer treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100